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Determinants of Occurrence of
Aortic Sclerosis in an Aging Population
Doan T. M. Ngo, BPHARM, PHD,* Aaron L. Sverdlov, MBBS,* Scott R. Willoughby, PHD,*
Angus K. Nightingale, MD,* Yuliy Y. Chirkov, PHD,* John J. McNeil, MBBS, PHD,†
John D. Horowitz, MBBS, PHD*
South Australia and Victoria, Australia
O B J E C T I V E S We sought to identify clinical, physiological, and biochemical correlates, including
markers of endothelial dysfunction and of tissue nitric oxide (NO) responsiveness, of the presence of
aortic sclerosis (ASc) in an aging population.
B A C KG ROUND Aortic sclerosis has been regarded predominantly as a precursor of hemodynam-
ically signiﬁcant aortic stenosis. However, ASc also represents an independent correlate of increased risk
of cardiovascular morbidity and mortality; the basis of this association is incompletely understood. The
assumption that the pathogenesis of aortic valve disease is similar to that of atherosclerosis has not been
supported by recent studies; rather there has been increasing evidence of a pathogenetic role of
inﬂammation and endothelial dysfunction. Furthermore, we have recently developed methodology for
echocardiographic quantitation of early aortic valve disease.
METHOD S Randomly selected subjects (n  253) ages 51 to 77 years underwent transthoracic
echocardiography; aortic valve ultrasonic backscatter score (AVBS) was used to quantitate echogenicity
of the aortic valve. Conventional coronary risk factors were identiﬁed. Integrity of NO generation/
response was assessed via: 1) plasma asymmetric dimethylarginine concentrations, as a marker of
endothelial dysfunction; 2) inhibition of platelet aggregation by the NO donor sodium nitroprusside, as
a measure of tissue NO responsiveness and also a coronary prognostic marker; and 3) aortic
augmentation index, as a measure of arterial stiffness/wave reﬂection. All putative correlations with AVBS
were examined by univariate and multiple linear regression analyses.
R E S U L T S On the basis of AVBS scores, ASc was present in 19.4% of subjects. The AVBS directly
correlated with patients’ age but inversely correlated with high-sensitivity C-reactive protein, creatinine
clearance, and platelet NO responsiveness. On multiple linear regression, ASc was associated with
impaired platelet NO responsiveness (  0.16, p  0.02), advancing age (  0.21, p  0.003), and
low body mass index (  0.23, p  0.001).
CONC L U S I O N S Aortic sclerosis is associated with platelet NO resistance rather than conventional
coronary risk factors: this might explain the increased thrombotic risk in ASc. (J Am Coll Cardiol Img
2009;2:919–27) © 2009 by the American College of Cardiology Foundation
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920ortic stenosis (AS) occurs as a result of a pro-
gressive increase in calcium deposition within
the aortic valve, leading to increased stiffness
and progressive narrowing of the valve.
emodynamically significant AS occurs in approxi-
ately 2% of adults older than 65 years of age (1,2).
he earlier stage of this process, known as aortic
valve) sclerosis (ASc)—which implies the presence of
bnormal aortic valve morphology in the absence of
arked obstruction—is even more common, affecting
pproximately 30% of adults older than age 65 (2,3).
See page 928
The clinical significance of ASc extends
beyond its status as a precursor of hemody-
namically significant AS. A number of care-
fully conducted studies have established that
ASc is an independent, incremental marker
of risk of cardiac events and cardiovascular
mortality (3,4). However there is current
uncertainty concerning both the major bio-
chemical mechanism(s) underlying the de-
velopment/progression of ASc and its asso-
ciation with coronary events.
It has been previously suggested that
the pathogenesis of AS involves an
“atherogenesis-like process” (5). However,
there is also evidence that atherogenesis is
not the central pathogenic process in AS.
Attempts to induce the development of
AS via hypercholesterolemia alone in an-
imal models have generally proved unsuc-
cessful (6,7), whereas lipid-lowering ther-
apy did not slow progression of AS in
the SALTIRE (Scottish Aortic Stenosis
and Lipid Lowering Trial, Impact on
Regression) (8) or SEAS (Simvastatin and
Ezetimibe in Aortic Stenosis) studies (9).
It is theoretically possible that a combi-
ation of endothelial dysfunction (i.e., of both valve
nd vasculature) and redox stress might contribute
oth to development of ASc and to its associated
ardiovascular risk. With regard to endothelial dys-
unction, it has been recently shown that calcific
odule formation in cell culture of aortic valve
broblasts is inhibited by nitric oxide (NO) (10).
linically, we have also shown that advanced AS is
ssociated with elevation of plasma concentrations
f asymmetric dimethylarginine (ADMA) (11), a
arker of endothelial dysfunction. Therefore, it is
robable that endothelial dysfunction develops at
ing
tor
ic
inome stage in the clinical course of AS and that NO Ts important for inhibition of development of valve
alcification.
A phenomenon closely related to but not identi-
al to endothelial dysfunction is NO resistance (12),
hich has been described extensively in the vascu-
ature (13,14) and also in platelets (15). In both
oronary arteries and platelets, this phenomenon of
O resistance is an independent marker of coro-
ary event risk (13,16). Although the basis for NO
esistance remains uncertain in the vasculature, the
ajor underlying mechanism in platelets is incre-
ental oxidative stress, with “scavenging” of NO by
2
 anion (15). If NO resistance were associated
ith propensity for development of ASc, this would
epresent both a basis for calcification and a poten-
ial link to coronary risk.
Previous investigations have generally regarded
Sc as a categorical variable. However, it is now
ossible to incorporate into analyses quantitation of
Sc, with aortic valve backscatter (AVBS) (17,18).
e have recently evaluated the basis for the asso-
iation between ASc development and increased
VBS in a rabbit model of mild AS (19). In this
odel, the correlation between AVBS and extent of
alve calcification was strong (R  0.76, p 
.001). Hence, AVBS reflects in part a quantitative
easure of overall valve calcification. This tech-
ique therefore facilitates evaluation of disease se-
erity and/or progression. In the current study, we
sed this technique to perform a cross-sectional
opulation study evaluating biochemical and phys-
ological correlates of the presence of ASc in aging
ndividuals. In particular, we sought to identify the
elative strengths of association of conventional coro-
ary risk factors versus parameters of endothelial func-
ion/NO effect as correlates of the presence of ASc.
E T H O D S
tudy subjects. The current investigation was a
rospectively defined substudy of the North West-
rn Adelaide Health Study (NWAHS). The
WAHS cohort participants were recruited by
elephone to conduct the interviews and the Elec-
ronic White Pages as the sampling frame. Within
ach household, the person who had their birthday
ast and was 18 years and older was selected for
nterview and invited to attend the clinic for a
iomedical examination. To minimize potential
ias due to differing probabilities of selection in the
ample, the data were weighted by region (western
nd northern health regions), age group, and sex.B B R E V I A T I O N S
N D A C R O N YM S
D 2-dimensional
CEI angiotensin-convert
nzyme inhibitor
DMA asymmetric
imethylarginine
IIRB angiotensin II recep
locker
Ix augmentation index
S aortic stenosis
Sc aortic sclerosis
VBS aortic valve ultrason
ackscatter score
MI bodymass index
SA body surface area
rCl creatinine clearance
RP C-reactive protein
s-CRP high-sensitivity
-reactive protein
DL low-density lipoprote
cholesterol)
V left ventricular
O nitric oxidehis cohort study did not recruit people residing in
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921nstitutions, such as nursing homes. However, peo-
le who had their own telephone number and were
iving in individual units attached to a nursing home
ere eligible to participate (20).
The current study population consisted of 255
onsecutive, randomly selected subjects from the
WAHS cohort from 51 to 77 years of age (mean
3.4  6 years), who had not previously undergone
ortic valve replacement. Of 255 subjects screened,
subjects were excluded due to the presence of
erminal cancer (n  1) and dextrocardia (n  1).
nformed consent was obtained from all subjects
efore study. The study was approved by the Ethics
f Human Research Committee of The Queen
lizabeth Hospital.
oppler echocardiography. Complete transthoracic
chocardiographic studies were performed in all
ubjects with a commercially available system (Vivid
[GE Vingmed, Horten, Norway], with a 2.5 MHz
hased array probe). M-mode and 2-dimensional
2D) echocardiograms with Doppler analysis were
btained for all subjects. Left ventricular (LV)
iameters and wall thicknesses were measured from
D-guided M-mode echocardiography. Mean and
eak pressure gradients across the aortic valve were
alculated with the modified Bernoulli equation,
ith continuous-wave Doppler recordings from the
ighest velocity available from any view. The aortic
alve area was computed with the continuity equa-
ion with standard methods.
ltrasound backscatter data analysis. Aortic valve
ackscatter values were obtained for all subjects
ith methods as previously published (17). Briefly,
D ultrasonic backscatter images of the aortic valves
ere obtained from standard parasternal long-axis
iews over 3 cardiac cycles with a zoom of 8 cm.
hree consecutive scans were acquired for each
tudy subject. Backscatter values from the blood
ool in the LV outflow tract and aortic root were
sed as reference values. Calibrated backscatter
alues were obtained by subtracting the average
lood pool value from the averaged backscatter
alues obtained from the aortic valves.
In all cases, valve morphology was categorized on
he basis of visual assessment, as previously de-
cribed (3,21). However, ASc was quantitated on
he basis of AVBS scores, and AVBS 16 dB was
sed as a definition of the presence of ASc (17).
iochemical measurements. Blood was collected
rom all subjects into heparinized tubes and cen-
rifuged at 4°C at 2,700 g for 20 min, and plasma
as stored at 80°C until assay. Concentrations
f ADMA in plasma were measured by high- nerformance liquid chromatography with the deriv-
tization reagent AccQ-Fluor (Waters, Milford,
assachusetts) after solid phase extraction, as pre-
iously described (22). Lipid profile, high-sensitivity
-reactive protein (hs-CRP), serum creatinine, cal-
ium, phosphate, and 1,25 dihydroxy cholecalciferol
vitamin D levels) were measured by a 125I radio-
mmunoassay (Immunodiagnostic Systems Ltd.,
olden, United Kingdom). Creatinine clearance
CrCl) was calculated according to the Cockcroft-
ault equation and indexed for body surface area
BSA) with the Dubois and Dubois formula.
latelet responsiveness to NO. Blood was collected in
lastic tubes containing 1:10 volume of acid citrate
nticoagulant (2 parts of 0.1 mol/l citric acid to 3
arts of 0.1 mol/l trisodium citrate); acidified citrate
as used to minimize deterioration of platelet
unction during experiments. Platelet aggregation
n whole blood was examined with a dual-channel
mpedance aggregometer (model 560, Chrono-
og, Havertown, Pennsylvania). Aggregation was
nduced with adenosine 5=-diphosphate at a final
oncentration of 2.5 mol/l. Aggregation was mon-
tored continually for 7 min, and responses were
ecorded for electrical impedance (ohms). In control
ests, physiologic saline was added in appropriate
olumes. Platelet responsiveness to NO was evalu-
ted via inhibition of aggregation in the presence of
he NO donor, sodium nitroprusside (SNP) (10
mol/l), as previously described (23).
easurement of augmentation index. Pulse wave-
orm analysis was performed noninvasively with a
ommercially available SphygmoCor system (AtCor
edical, Sydney, Australia), as previously described
24). All subjects were asked to lie down in a quiet
oom for 15 min before the procedure. Briefly, pulse
aveform analysis was computed from the radial
rtery at the wrist and recorded by applanation
onometry with a high-fidelity micromanometer.
hree recordings of 10 sequential waveforms were
cquired for each subject; a validated, generalized
ransfer function was used to generate the correspond-
ng central aortic pressure waveform, from which
ugmentation index (AIx) was derived. Only high-
uality recordings with in-device quality index 90%
ere used. All augmentation indexes were corrected
or a standard heart rate of 75 beats/min.
tatistical analyses. All data are expressed as mean
SD unless otherwise stated. Normal distribution
as tested for all continuous variables, and skewed
ata were normalized either by log or square root
ransformation. Comparisons between groups for
ormally distributed data were performed with
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922onpaired t tests and, comparisons for nonparamet-
ic data were made with the Mann-Whitney test.
orrelations between transformed, continuous
onparametric data were made with linear regres-
ion. Stepwise multiple linear regression analyses
ere performed to assess independent predictors of
VBS scores. Included variables to predict AVBS
ores were: age, sex, smoking history, previous
schemic events/angina, diabetes mellitus, hyper-
holesterolemia, hypertension, calculated CrCL,
alcium-phosphate product (CaxPO4) levels, vita-
in D levels, body mass index (BMI), hs-CRP,
Ix, ADMA concentrations, and platelet responses
o SNP. Binary logistic backward regression analy-
is was also performed with the aforementioned
ariables but with the presence of ASc on backscat-
er as a categorical variable to evaluate whether
resence of elevated AVBS scores per se identified
imilar associations as those seen with stepwise
ultiple linear regression. All analyses were per-
ormed with SPSS version 13 software (SPSS,
hicago, Illinois), and a p value of 0.05 was
onsidered to be statistically significant.
E S U L T S
ubject characteristics. Mean AVBS score was 12.2
5
0
5
0
5
No Yes
Aortic Valve Sclerosis Presence
Correlation of AVBS and Visual Assessment Score
n of aortic valve backscatter scores (AVBS) with visual assessment
ubjects without and with aortic sclerosis. There was a signiﬁcant
in AVBS between groups (11.2  3.9 dB vs. 14.9  4.5 dB, respec-
0.001). Means and interquartile ranges are depicted. Whiskers
minimum and maximum values..4 dB. In 19.4% of subjects, AVBS was 16 dB, morresponding to the chosen definition of ASc (17).
n visual assessment, aortic valve morphology was
bnormal in 25.4% of subjects; such subjects had
ignificantly higher (p  0.001) AVBS scores than
hose without visual assessment criteria for ASc
Fig. 1). Mean ejection fraction was 68.3  8.6%
only 3 subjects had ejection fraction 40%); mean
V mass index was 113.27  31.1 g/m2; mean
nterventricular wall thickness was 1.04  0.17 cm;
ean aortic valve pressure gradient was 7 3.8 mm
g. There were no statistically significant echocar-
iographic differences between those with and
hose without ASc with respect to LV ejection
raction, LV mass index, interventricular wall thick-
ess, and aortic valve pressure gradient. There were
o subjects with bicuspid aortic valve.
Baseline clinical characteristics are summarized
n Table 1 for subjects with and without ASc.
verall, there was a high proportion (30.8%) of
bese subjects (BMI 30 kg/m2). Multiple (3)
oronary risk factors were present in 32% of sub-
ects. One-third of subjects were on statin treatment
ith a similar proportion receiving angiotensin-
onverting enzyme inhibitors (ACEI)/angiotensin
I receptor blockers (AIIRBs). Seventy-nine per-
ent of hypertensive patients were receiving ACEI/
IIRBs, whereas 55% of hypercholesterolemic
atients were treated with statins. There were
tatistically significant differences between those
ubjects with ASc and those without, with respect
o age and BMI (p  0.05 in both cases) only.
iochemical data. Biochemical findings are summa-
ized in Table 2. Plasma cholesterol concentrations
ere elevated beyond normal (5.5 mmol/l) in
6.4% of subjects at entry. In general, renal function
as well-preserved: there were no patients on dial-
sis, with only 2 subjects with CrCl 30 ml/min/
.73 m2. Vitamin D levels were generally toward
he lower end of the reference normal range for the
aboratory assay (normal range 50 to 160 nmol/l)
25). Comparisons between subjects with and with-
ut ASc revealed that CrCl was significantly greater
n subjects without ASc.
ndothelial function and platelet responsiveness to
O. Mean AIx was 27.6  8.5% (normal range:
5  16%), substantially greater than values for
ormal adults (26); these findings suggested in-
reased arterial stiffness/wave reflection in this sub-
ect cohort. Similarly, mean platelet antiaggregatory
esponse to SNP was a relatively low 33  27%
normal range: 54  24%), consistent with some
egree of platelet resistance to NO (22). However,2
2
1
1
A
or
tic
 V
al
ve
 B
ac
ks
ca
tte
r (
dB
)
Figure 1.
Compariso
scores in s
difference
tively, p ean plasma ADMA concentrations were within
t

U
s
c
t
l
h
a
s
C
t
c
b
I
b
T
A
p
n
c
A
t
p
c
A
se; M
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 8 , 2 0 0 9
A U G U S T 2 0 0 9 : 9 1 9 – 2 7
Ngo et al.
Predictors of Aortic Sclerosis in Aging Population
923he previously described normal range (0.52  0.08
mol/l [normal range: 0.50  0.08 mol/l]) (22,27).
nivariate correlations with AVBS scores. These are
ummarized in Table 3. There was a significant
orrelation between AVBS scores and age. Although
otal cholesterol and low-density lipoprotein (LDL)
evels did not correlate with AVBS scores, high
igh-density lipoprotein levels were significantly
ssociated with high AVBS scores. There was a
ignificant inverse correlation between calculated
rCL (corrected for BSA) and AVBS scores. Al-
hough there was no correlation between AVBS and
alcium levels, there were borderline correlations
etween AVBS and phosphate or CaxPO4 levels.
Table 1. Patient Characteristics: Clinical Data
Characteristic
No ASc (AVBS
(n 
Age, mean  SD (yrs) 63
BMI (kg/m2) 28.5
Sex (% male) 42
History of hypercholesterolemia 61
Statin therapy 30
Previous angina/MI 11
ACEI/AIIRB therapy 34
Hypertension 44
Family history of CVD 51
Smoking 14
Diabetes mellitus 10
Subjects with 2 cardiovascular risk factors 31
History of CVA 3
Calcium supplementation 16
Vitamin D supplementation 2
ACEI  angiotensin-converting enzyme inhibitor; AIIRB  angiotensin II recepto
body mass index; CVA  cerebrovascular accident; CVD  cardiovascular disea
Table 2. Patient Characteristics: Baseline Biochemical Data
No ASc (AVBS S
Total cholesterol (mmol/l) 5
LDL (mmol/l) 2.9
HDL (mmol/l) 1.3
Calcium (mmol/l) 2.2
Phosphate (mmol/l) 1
CaxPO4 2.3
Vitamin D (nmol/l) 71.5
CrCL (indexed for BSA) (ml/min/1.73 m2) 84.2
hs-CRP (mg/l) 3.5
AIx (%) 25.7
% platelet responsiveness to SNP 34.8
ADMA (mol/l) 0.52
Expressed as mean  SD.
ADMA  asymmetric dimethylarginine; AIx  augmentation index; BSA  bo
HDL  high-density lipoprotein; hs-CRP  high-sensitivity C-reactive protein; L
in Table 1.mportantly, there was no significant relationship
etween vitamin D levels and AVBS scores.
BMI inversely correlated with AVBS scores.
here was also an inverse correlation between
VBS scores and hs-CRP levels. With regard to
arameters of endothelial function/NO responsive-
ess in this study population, there was no signifi-
ant correlation between AVBS scores and either
Ix or plasma ADMA concentrations. However,
here was a significant inverse correlation between
latelet responsiveness to SNP and AVBS scores.
Of interest, none of the “traditional” major
oronary risk factors were significant correlates of
VBS (p  0.2 in all cases); nor did treatment
re <16 dB)
4)
ASc (AVBS Score >16 dB)
(n  49) p Value
.0 64.9  9 0.045
.1 26.7  4.2 0.019
49% 0.372
53.1% 0.565
38.8% 0.268
20.4% 0.114
25% 0.193
32.7% 0.146
57.1% 0.439
12.2% 0.649
10.2% 0.898
32.7% 0.879
4.1% 0.835
16.7% 1
0% 0.327
cker; ASc  aortic sclerosis; AVBS  aortic valve ultrasonic backscatter; BMI 
I  myocardial infarction.
<16 dB) ASc (AVBS Score >16 dB) p Value
4.9 1 0.774
2.8 0.7 0.549
1.4 0.4 0.126
2.2 0.1 0.7
1 0.2 0.129
2.3 0.5 0.236
79 32 0.138
76 20 0.022
4 5.6 0.576
24.3 9.4 0.355
26.6 25.4 0.084
0.52 0.07 0.746
rface area; CaxPO4 calcium-phosphate product; CrCL  creatinine clearance;
low-density lipoprotein; SNP  sodium nitroprusside; other abbreviations asSco
20
 6
 5
%
.8%
.5%
.9%
.8%
.1%
%
.8%
.8%
.5%
.5%
.7%
%
r blocore
1
0.9
0.3
0.1
0.2
0.4
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3.6
8.1
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0.08
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924ith either statins or ACEIs apparently interact
ith AVBS.
There was a strong positive correlation between
MI and CrCl indexed for BSA, which persisted at
 0.001 level even with calculation of CrCl with
he modified diet in renal disease equation (28),
here body weight is not a part of the equation
p  0.001). These data therefore suggest strongly
hat, even after indexing for BSA, CrCl calculation
s not a reliable estimate of renal function for obese
ubjects. This finding was recognized as having
mportant implications in the multiple regression
nalyses, as regards interpretation of both BMI and
rCl data.
tepwise multiple linear regression analyses. Table 4
ocuments results of stepwise multiple linear re-
ression analysis. Advanced age was positively as-
ociated with high AVBS scores (  0.2, p 
.004), whereas platelet antiaggregatory responsive-
ess to SNP (0.16, p 0.02) and BMI (
0.23, p  0.001) was negatively associated.
inary logistic backward regression. Binary logistic
ackward regression analysis with the presence of
Sc on backscatter as a categorical variable pro-
uced similar results but with weaker statistical
ower. Advanced age was positively (and signifi-
antly) associated with the presence of ASc (p 
.008,   0.08, odds ratio: 1.1, 95% confidence
nterval: 1.02 to 1.15), whereas platelet antiaggre-
atory responsiveness to SNP (p  0.054,  
0.122, odds ratio: 0.885, 95% confidence interval:
.781 to 1.002) and BMI (p 0.118, 4, odds
atio: 0.018, 95% confidence interval: 0 to 2.776)
ended to be negatively associated.
I S C U S S I O N
revious evaluations of the epidemiology of ASc
Table 3. Univariate Correlates of AVBS Scores
Parameter p Value  Coefﬁcient
Age 0.005 0.18
HDL levels 0.016 0.154
CrCL indexed for BSA 0.001 0.204
Phosphate levels 0.068 0.116
CaxPO4 0.084 0.11
BMI 0.001 0.245
hs-CRP 0.028 0.14
% platelet responsiveness to SNP 0.017 0.162
Only parameters with p 0.1 for correlation with AVBS scores are shown. Data
for HDL levels, BMI, hs-CRP, and % platelet responsiveness to SNP were
transformed via log transformation to achieve normal distributions.
Abbreviations as in Tables 1 and 2.ave been performed in a substantially larger pop-lation of aging individuals as components of the
ardiovascular Health Study (2,3,29). These inves-
igations have focused on putative correlations be-
ween conventional coronary risk factors and the
resence/development of ASc (2,3,29): in general
ignificant correlations have been documented in
he case of some but not all coronary risk factors. In
ontrast, the current study evaluated a substantially
maller subject cohort but had the advantage of
uantitative rather than qualitative assessment of
alve thickening, thus increasing the power of the
tudy. Furthermore, the current study focused ad-
itionally on the premise that factors related to NO
esponse at the level of the platelets and vasculature
ight predispose to development of ASc in hu-
ans, just as NO negatively modulates valve calci-
cation in vitro (10).
The results of the current study are therefore
mportant with regard to both positive and negative
ndings: platelet NO resistance was a significant
orrelate of ASc, whereas all conventional coro-
ary risk factors did not approach such significant
ssociation.
Apart from the Cardiovascular Health Study
2,3,29), other investigations have examined deter-
inants of progression of AS. In general, these
nvestigations have considered patients in whom
oderate AS was present at initial evaluation. Such
tudies tend to identify coronary risk factors, in-
luding male sex, as correlates of rapid progression
2,30–33)—apart from the finding that AS “pro-
ression” is seen to accelerate as the disease ad-
ances. In contrast, the study of Novaro et al. (29),
he only previously reported investigation concern-
ng correlates of ASc, found a weak correlation with
levation of LDL cholesterol and no association
etween ASc and other coronary risk factors. Fur-
hermore, evaluation of aortic valve calcification
ithin the MESA (Multi-Ethnic Study of Athero-
clerosis) cohort (34,35) indicated that both diabe-
es and metabolic syndrome were correlates of de
ovo valve calcification but not of its progression.
The central methodology used in the current
tudy was the quantitation of AVBS with the defi-
Table 4. Variables Independently Associated With High AVBS
Scores After Stepwise Multiple Linear Regression Analysis
Parameter  Coefﬁcient p Value
BMI 0.23 0.001
Age 0.20 0.004
Platelet responsiveness to SNP 0.16 0.02Abbreviations as in Tables 1 and 2.
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925ition of ASc chosen to be AVBS 16 dB (16).
his parameter had strong but incomplete concor-
ance with visual assessment of valve morphology
Fig. 1) but had the advantage of substantially
ncreasing the power of the study. For example, the
ssociation between platelet NO resistance and ASc
as of borderline significance only on categorical
nalysis of AVBS values (Table 2) but, with quan-
itative analysis, demonstrated statistically signifi-
ant association both on univariate (Table 3) and on
ultivariate (Table 4) analyses.
In the current study, ASc was associated with
latelet resistance to NO. This finding is of poten-
ial relevance to the association between ASc and
hrombotic events (3,4,16). Furthermore, tissue re-
istance to NO might also contribute to the calci-
cation process per se (9). The major biochemical
echanism underlying NO resistance is “scaveng-
ng” of NO by O2
 anion (15), suggesting in turn
ncremental redox stress in association with ASc.
onversely, plasma concentrations of ADMA,
hich potentially can limit endogenous NO forma-
ion, were not elevated. This suggests that at the
arly stages of AS development, endothelial dys-
unction might be limited to accelerated NO clear-
nce by O2
 anion; the previously observed eleva-
ion of ADMA levels (11) presumably develops
nly in patients with more advanced disease.
There was no association between presence of
Sc and any of the coronary risk factors evaluated.
lthough these data are consistent with the low
oncordance between the presence of AS and cor-
nary artery disease (36), they contrast to some
xtent with previous evaluations (30,32,36). In 2
revious studies (30,31), elevation of LDL choles-
erol levels was associated with the presence of ASc.
t is possible that the results might have been
nfluenced by widespread pharmacotherapy, for ex-
mple with statins, ACEI, and AIIRBs. However,
verall these data suggest that pathogenetic factors
or ASc differ from those for atherosclerosis.
It is also of some interest that the presence of
Sc was not associated with increased AIx, a
arker of arterial stiffness (as well as endothelial
unction) (37–39). Therefore, these findings tend to
issociate ASc from the arterial degenerative
hanges underlying systolic hypertension (40).
Although inflammatory activation is present as a
omponent of histological appearances in ASc
41,42), plasma hs-CRP levels were not correlated
ith ASc in this study. These results are similar to
hose in a related recent evaluation (36). As regards
he putative association between plasma vitamin D aevels and ASc, this association has been evaluated
o date only in advanced disease (42) and is most
learly evident in patients with chronic renal fail-
re (43,44).
Advanced age was found to be an independent
orrelate of AVBS values, consistent with the find-
ngs in the most recent study (36) and with previous
eports in AS patients (1–3). The implication of
his finding is that the biochemical nexus between
dvanced age and development of ASc remains to
e identified.
tudy limitations. The results of the study as regards
enal dysfunction are somewhat equivocal. In the
ubject population examined, renal function was
enerally well preserved, but low CrCl was a uni-
ariate correlate of high AVBS values. Creatinine
learance was “corrected” for BSA via the Dubois
nd Dubois formula, but a direct association be-
ween BMI and “corrected” CrCl persisted. Fur-
hermore, CrCl was a strong inverse univariate
orrelate of AVBS. Therefore, it is possible that
ome relationship between renal dysfunction and
VBS has been obscured by inadequate correction
or obesity. However, the overall conclusion from
he current findings is that CrCl does not markedly
ffect development of ASc in a population with
verall well-preserved renal function. Therefore,
he finding that BMI inversely correlated with
VBS scores might also be partially confounded by
his interaction with renal function estimates. How-
ver, it remains possible, as suggested by previous
tudies in advanced AS (45), that there is a link
etween low BMI and propensity toward develop-
ent of ASc.
It is also important to emphasize that the current
egative results as regards the association between
onventional coronary risk factors and the presence
f ASc in no way invalidate the largely contrary
ndings of the larger Cardiovascular Health Study
2,3,29). Lack of demonstration of such associa-
ions might in part reflect type II error (in particular
s regards diabetes mellitus, given the small propor-
ion of diabetic subjects) and/or the influences of
ore extensive background pharmacotherapy. The
esults of the current study also do not in themselves
alidate increased backscatter as a marker either of
isk of cardiac events or of a potentially accelerated
ate of development of AS.
O N C L U S I O N S
he presence of ASc in this aging population was
ssociated with platelet NO resistance, a finding
t
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926hat provides a potential mechanism for the pro-
ensity for acute coronary syndromes in this condi-
ion. In contrast, neither LDL elevation nor hyper-
ension or any of the other “conventional” coronary
isk factors examined was predictive of presence of
Sc. This further emphasizes differences in risk
actors for atheroma and for ASc. Both theseJ Pharmacol 2009;602:28–35.
West Adelaide Hea
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